Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

New pages

More actions
New pages
Hide bots | Show redirects | Show reviewed edits
(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)

19 May 2026

  • 06:2206:22, 19 May 2026 CBN (hist | edit) [1,144 bytes] MDElliottMD (talk | contribs) (Create Cannabinol (CBN) medicine stub: minor phytocannabinoid, THC oxidation product, weak CB1 partial agonist, popularly framed as a sleep cannabinoid with sparse controlled evidence. Cites Russo 2011 entourage-effect review (PMID 21749363).)
  • 03:1603:16, 19 May 2026 Lixisenatide (hist | edit) [807 bytes] MDElliottMD (talk | contribs) (Create Lixisenatide stub: short-acting GLP-1 receptor agonist (Adlyxin / Lyxumia, FDA 2016, withdrawn from US market 2023). Closes last redlink in Category:GLP-1 receptor agonists.)

18 May 2026

16 May 2026

15 May 2026

(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)